Immunotherapy Coverage from Every Angle
Advertisement
Advertisement

News

SABCS 2024: Margetuximab vs Trastuzumab Combinations in Early HER2-Positive Breast Cancer
SABCS 2024: Correlation of Biomarkers With Outcomes in Early Triple-Negative Breast Cancer
Combination of Sintilimab and Nab-Paclitaxel in Advanced Squamous NSCLC
For Advanced Squamous Cell Skin Cancer: FDA Approves PD-L1–Blocking Antibody
SABCS 2024: T-DXd vs Chemotherapy in Previously Treated Metastatic Breast Cancer
Metformin: An Effective Treatment of Lung Cancer Among Patients With Obesity?
SABCS 2024: HER3-DXd Under Study in HR-Positive, HER2-Negative Early Breast Cancer
Under Study in Squamous Cell Skin Cancer: Neoantigen Therapy Plus Pembrolizumab
New Bispecific Antibody Granted Approval in NSCLC Harboring NRG1 Gene Fusion
Investigating Immunotherapy Resistance in Merkel Cell Carcinoma
Immune Biomarkers as Predictors of Survival and Risk in Patients With Melanoma
Immunotherapy Combination Under Study in High-Risk Resectable Melanoma
Advanced Merkel Cell Carcinoma: How Effective Is Immunotherapy Rechallenge?
5-Year Outcomes From NADIM Trial Support Perioperative Chemoimmunotherapy in NSCLC
SITC 2024: Elucidating the Therapeutically Relevant Mechanisms of TROP2 in Breast Cancer
SITC 2024: Update on Use of HDAC Inhibitor Plus Nivolumab in Advanced Melanoma
SITC 2024: Adding IL-4 Inhibitor to PD-1 Inhibitor Therapy for ER-Positive Breast Cancer
New Application for Accelerated Approval for Dato-DXd in Advanced EGFR-Mutated NSCLC
SITC 2024: Addition of Radiotherapy to Immunotherapy in Advanced Merkel Cell Carcinoma
SITC 2024: CRISPR Editing Yields New B-Cell Strategies for Treating HER2-Positive Breast Cancer
SITC 2024: Comparing Types of Tumor Infiltrating Lymphocytes in Merkel Cell Carcinoma
SITC 2024: Novel Method to Predict, Assess Immunotherapy Efficacy in NSCLC
SITC 2024: Potential Biomarker of Disease Progression After Immunotherapy for Advanced Melanoma
SITC 2024: Overcoming PARP Inhibitor Resistance in BRCA1-Mutated Breast Cancer
SITC 2024: Updated Overall Survival From PERLA Trial in Metastatic Nonsquamous NSCLC
SITC 2024: Efficacy Outcomes With TIL Therapy for Advanced Melanoma
SITC 2024: Can Machine Learning Identify Treatment-Specific Outcomes and Biomarkers in NSCLC?
Radiotherapy Strategy for Enhancing Immunotherapy for Triple-Negative Breast Cancer
Is Immunotherapy Efficacious for Children and Adolescents With Melanoma?
Ivonescimab Plus Chemotherapy for Triple-Negative Breast Cancer
Relapse Patterns From Long-Term Subgroup Analysis of IMpower010
Using Machine Learning Model to Predict NSCLC Progression After Upfront Pembrolizumab
Copyright © 2024 National Comprehensive Cancer Network, All Rights Reserved
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.